Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KARD
Strong SellSinkerKardigan, Inc. · Healthcare · United States · $1.9B · Avg Vol: $5M/d
11
StockRankGet insider-trade alerts
Q
35
V
28
M
23
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | — | — | — | — |
| EPS | -1.42 | -3.20 | -3.09 | -4.54 | -3.20 | — |
| Shares | 89.3M | 89.3M | 93.5M | — | — | — |
| Debt | 9.5M | 13.8M | 13.3M | — | — | — |
| Equity | -83.2M | -250.3M | — | — | — | — |
| Op CF | -18.8M | -151.1M | -205.6M | — | — | — |
| Inv CF | -36.4M | -237.0M | — | — | — | — |
| Fin CF | 105.0M | 447.8M | — | — | — | — |
Loading 1Y...
PRICE (1Y)-8.7%
SMA 50SMA 200
Close
$18.69
RSI (14)
42.7
SCORE BREAKDOWN
Quality
35
ROIC
-57.1%13.9
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-40.3%8.9
Piotroski
559.7
Int. Cover
—N/A
D/E Ratio
0.02x79.5
Current Ratio
8.72x84.9
Value
28
P/E (TTM)
—N/A
EV/EBITDA
-5.1x25.0
P/FCF
—N/A
P/B
3.2x44.2
P/S
—N/A
Div Yield
—N/A
Momentum
23
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
-6.2%12.1
EPS Rev 12W
—N/A
EPS Improve
-4%20.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.9B
P/E (Forward)
-6.5x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KARD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KARD | Kardigan, Inc.(you) | $1.9B | 11 | Strong Sell |
| BRVE | Braveheart Bio, Inc. | $1.9B | 11 | Strong Sell |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.8B | 11 | Strong Sell |
| INBX | Inhibrx Biosciences, Inc. | $1.8B | 13 | Strong Sell |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.1B | 11 | Strong Sell |
| TSHA | Taysha Gene Therapies, Inc. | $1.9B | 13 | Strong Sell |
| KLRA | Kailera Therapeutics, Inc. | $2.1B | 11 | Strong Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 13 | Strong Sell |
| AVLN | Avalyn Pharma Inc. | $1.5B | 10 | Strong Sell |
| NTLA | Intellia Therapeutics, Inc. | $1.8B | 7 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%